MorphoSys AG
morphosys.comNo Longer Reporting
The company has not filed an annual or quarterly report since its FY2023 20-F, filed Mar 13, 2024. Its latest SEC filing is a 15-12G from Oct 17, 2024.
20-F for FY2023, filed Mar 13, 2024
The sections below describe the company as of the FY2023 annual report.
What Did They Do?
Develops and commercializes cancer medicines for patients, while advancing its own oncology drug candidates and antibody programs with pharmaceutical partners.
20-F for FY2023, filed Mar 13, 2024MorphoSys is a global biotechnology company focused on the development and commercialization of innovative cancer medicines.View ↗
MorphoSys is focused on the development and commercialization of innovative cancer medicines, advancing its mid-to-late-stage oncology…View ↗
Our key partner programs, developed via our legacy antibody technology platform, continue to mature and have the potential to generate…View ↗
Who Were Their Customers?
Pharmaceutical and biotechnology companies work with MorphoSys on drug programs; Janssen, McKesson and Incyte were among its revenue customers.
20-F for FY2023, filed Mar 13, 2024
20-F for FY2023, filed Mar 13, 2024
Did Revenues Turn Into Profits?
No. It lost EUR 189.7M in .
20-F for FY2023, filed Mar 14, 2024
How Were They Changing?
From antibody discovery to cancer medicines
The older report described discovery and development across proprietary and partner programs, including antibody-platform work for pharmaceutical partners. The latest report centers on developing and commercializing cancer medicines, especially its own oncology candidates, while partner-developed antibody programs are legacy collaborations.
20-F for FY2020, filed Mar 15, 2021 20-F for FY2023, filed Mar 13, 2024We are a commercial-stage biopharmaceutical company devoted to the discovery, development and commercialization of innovative and…View ↗
MorphoSys is a global biotechnology company focused on the development and commercialization of innovative cancer medicines.View ↗
MorphoSys is focused on the development and commercialization of innovative cancer medicines, advancing its mid-to-late-stage oncology…View ↗
Our key partner programs, developed via our legacy antibody technology platform, continue to mature and have the potential to generate…View ↗
Loading...
